gp2 peptide
Vaccineexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2007 (NCT00524277)
Timeline
Indications
Studied for
Mechanism of action
- Receptor protein-tyrosine kinase erbB-2Immunity, active
ERBB2 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- gp2 peptide
- gp2 peptide
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03014076 | Phase 1 | Jan 1, 2008 | Cancer Insight, LLC |
| NCT00524277 | Phase 2 | Jan 1, 2007 | Generex Biotechnology Corp., Norwell, Inc., United States Army, University of Texas at Houston |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Cancer Insight, LLC | For profit | 1 | 1 | 1 | 2008 |
| Generex Biotechnology Corp. | For profit | 1 | 0 | 1 | 2007 |
| Norwell, Inc. | For profit | 1 | 0 | 1 | 2007 |
| United States Army | Government | 1 | 1 | 1 | 2007 |
| University of Texas at Houston | Academic/Hospital | 1 | 0 | 1 | 2007 |
5 organizations
Page 1 / 1